Bioequivalence Study of Two Orally Disintegrating Risperidone Formulations, Risperdal OD![]() |
Kang, Ga-Eun
(Department of Pharmacology, Chonnam National University Medical School)
Kim, Jin (Division of Clinical Pharmacology, Chonnam National University Hospital) Bae, Kyung-Yeol (Department of Psychiatry, Chonnam National University Medical School) Shin, Hee-Young (Department of Biomedical Science, Chonnam National University Medical School) Jeong, Seong-Wook (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School) Yoon, Jin-Sang (Department of Psychiatry, Chonnam National University Medical School) Kim, Jong-Keun (Department of Pharmacology, Chonnam National University Medical School) |
1 | 대한신경정신의학회. 신경정신의학. 2nd ed. 중앙문화사, 서울. 2005. |
2 | 리스페달 퀵릿 정 상세허가정보. (주)한국얀센2009 |
3 | Hauschke D, Steinijans V, Pigeot I. Bioequivalence studies in drug development: methods and applications. John Wiley & Sons Inc, London. 2007. |
4 | 권광일, 김옥희, 김종국, 김주일, 배균섭, 사홍기, 이용복, 이화정, 최선옥. 생물학적동등성의 이해. 신일상사, 서울. 2006. |
5 | Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol, 1991;29(1): 1-8. |
6 | Bhatt J, Subbaiah G, Singh S. Liquid chroma tography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. Rapid Commun Mass Spectrom, 2006;20(14):2109-2114. DOI ScienceOn |
7 | Huang MZ, Shentu JZ, Chen JC, Liu J, Zhou HL. Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers. J Zhejiang Univ Sci B, 2008;9(2): 114-120. DOI ScienceOn |
8 | Cho HY, Park EJ, Kang HA, Baek SH, Lee S, Park CH, Moon JD, Lee YB. Bioequivalence of Rispen Tablet to Risperdal Tablet(Risperidone 2mg). J Kor Pharm Sci, 2004;13:271-277. |
9 | Machin D, Campbell MJ. Design of studies for medical research. John Wiley & Sons Ltd, L-ondon. 2005. |
10 | van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther, 2003; 25(6):1687-1699. DOI ScienceOn |
11 | Sastry SV, Nyshadham JR, Fix JA. Recent tehnological advances in oral drug delivery a review. Pharm Sci Technolo Today, 2003;3(4):138-145. |
12 | US Food and Drug Administration, CDER Guidancd for industry. Orally disintegrating tablets. 2008. |
13 | 식품의약품안전청 고시 제 2008-22호, 생물학적동등성시험기준. |
14 | Hirani JJ, Rathod DA, Vadalia KR. Orally disintegrating tablets: A review. Tropical Journal of Pharmaceutical Research, 2009; 8(2):161-172. |
15 | Lechat P, Vermeulen D, Heald D. Risperidone QuicksolvTM/QuickletTM pharmacokinetics in humans. A summary of the pharmacokinetic data on the bioavailability/bioequivalence of Quicksolv TM/ Quicklet TM and commercially available tablets. Johnson & Johnson Pharmaceuticla Research & Development, a division of Janssen Pharmaceutica NV, 2001. |
![]() |